Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • TAM Receptor
    (53)
  • c-Met/HGFR
    (16)
  • FLT
    (13)
  • Apoptosis
    (7)
  • VEGFR
    (7)
  • c-Kit
    (6)
  • Trk receptor
    (3)
  • c-RET
    (3)
  • FGFR
    (2)
  • ADC Antibody
    (1)
Filter
Search Result
Results for "

TAM Receptor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    55
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    5
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    6
    TargetMol | Recombinant_Protein
gilteritinib
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Bemcentinib
R428, BGB324
T62691037624-75-1
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Cabozantinib
XL184, BMS-907351
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035 1.3 4.6 7 11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
  • Inquiry Price
Size
QTY
sitravatinib
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
  • Inquiry Price
Size
QTY
2-D08
T7379144707-18-6
2-D08 is a synthetic flavone that inhibits sumoylation, also inhibits Axl with an IC50 of 0.49 nM.2-D08 showed anti-aggregatory and neuroprotective effect.
  • Inquiry Price
Size
QTY
TAM-IN-2
T130742135642-56-5
TAM-IN-2 is an inhibitor of TAM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
UNC2250
T19681493694-70-4
UNC2250 is an effective and specific Mer inhibitor (IC50=1.7 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
BMS-777607
T26581196681-44-3
BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.
  • Inquiry Price
Size
QTY
Astragalus polysaccharide
Astragalus Polysacharin
T2S083789250-26-0
Astragalus polysaccharide, a natural product derived from Astragalus propinquus, exhibits anticancer activity and has been shown to be effective in hepatocellular carcinoma (HCC) by inhibiting the M2 polarization of tumor-associated macrophages (TAM).
  • Inquiry Price
Size
QTY
S49076
T32741265965-22-7
S49076 is a novel and potent inhibitor of MET, AXL MER, and FGFR1 2 3, effectively blocking cellular phosphorylation of MET, AXL, and FGFRs.
  • Inquiry Price
Size
QTY
Cabozantinib hydrochloride
XL184, Cabozantinib hydrochloride (849217-68-1(free base)), BMS-907351
T51641817759-42-4
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
  • Inquiry Price
Size
QTY
AXL-IN-14
T733102947506-65-0
AXL-IN-14 is a potent, orally active inhibitor of AXL with an IC50 of 0.8 nM that effectively suppresses Gas6 AXL-mediated cell migration and invasion, reduces the expression of p-AXL and p-AKT proteins, and demonstrates anti-tumor activity [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Emactuzumab
RO 5509554, RG 7155
T767761448221-67-7
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
  • Inquiry Price
Size
QTY
Enapotamab
T768641912423-61-0
Enapotamab is an AXL UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin).
  • Inquiry Price
Size
QTY
AXL-IN-15
T790451954722-22-5
AXL-IN-15 (cpd391) is a potent Axl inhibitor with a dissociation constant (K i) and half-maximal inhibitory concentration (IC50) of less than 1 nanomolar (nM), suitable for cancer research [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Axl-IN-16
T79969
Axl-IN-16, a dual Axl HIF inhibitor, promotes Flammulina velutipes fruiting body formation and suppresses hypoxia-inducible factor activity along with receptor tyrosine kinase expression [1].
  • Inquiry Price
Size
QTY
AXL-IN-13
T733002376928-82-2In house
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
  • Inquiry Price
6-8 weeks
Size
QTY
Gilteritinib hemifumarate
ASP2215 hemifumarate
T719731254053-84-3
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
  • Inquiry Price
6-8 weeks
Size
QTY
MerTK/Axl-IN-1
T2005173036009-40-9
MerTK Axl-IN-1 (Compound A-910) is a potent and selective dual inhibitor of MerTK Axl, exhibiting IC50 values of 4.2 nM and 8.8 nM in Ba F3 cells, and 0.2 nM and 0.9 nM in HTRF cells, respectively. It effectively inhibits pMerTK in vivo and possesses a long half-life and high oral bioavailability.
  • Inquiry Price
3-6 months
Size
QTY
MerTK-IN-1
T2009633036376-10-7
MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.
  • Inquiry Price
3-6 months
Size
QTY
Protein kinase inhibitor 10
T205111871317-00-9
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.
  • Inquiry Price
10-14 weeks
Size
QTY
C-Met/Axl-IN-1
T205497
C-Met Axl-IN-1 (Compound 22a) is an oral, selective type II c-Met Axl inhibitor with IC50 values of 1 nM and 10 nM, respectively. It effectively suppresses tumor cell proliferation, induces cell cycle arrest, and apoptosis (apoptosis), showcasing potent anti-tumor activity.
  • Inquiry Price
Size
QTY
Tilvestamab
BGB149, BGB 149
T767232226775-26-2
Tilvestamab (BGB149) is a humanized antibody targeting AXL with anti-tumor and anti-fibrotic activity, inhibiting Gas6-stimulated AXL activation and tumor progression in 786-0 RCC cells, used in cancer research.
  • Inquiry Price
Size
QTY
Mecbotamab vedotin
CAB-Axl-ADC, CAB-anTi-Axl-ADC, BA3011
T9901A-2252460400-64-8
Mecbotamab vedotin (BA301) is an inhibitory IgG1 antibody that targets human tyrosine kinase receptor AXL and the humanized murine monoclonal BA301 γ1 chain. It can be utilized in the preparation of immunoconjugates for research into cancers expressing the Axl type.
  • Inquiry Price
Size
QTY